A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Inclusion Criteria:

• Persons with a progranulin gene mutation and at risk of developing FTD symptoms asevidenced by a biomarker, or persons with a progranulin gene mutation and diagnosedwith FTD.

• If symptomatic, one or more of the criteria for the diagnosis of possible behavioralvariant FTD, or a diagnosis of Primary Progressive Aphasia.

• Study partner who consents to study participation and who cares for/visits theparticipant daily for at least 5 hours per week.

• Written informed consent must be obtained and documented (from the participant or,where jurisdictions allow it, from their legal decision maker).

Exclusion Criteria:

• Dementia due to a condition other than FTD including, but not limited to,Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, Huntingtondisease, or vascular dementia.

• Known history of severe allergic, anaphylactic, or other hypersensitivity reactionsto chimeric, human, or humanized antibodies or fusion proteins.

• Current uncontrolled hypertension, diabetes mellitus or thyroid disease. Clinicallysignificant heart disease, liver disease or kidney disease. History or evidence ofclinically significant brain disease other than FTD.

• Females who are pregnant or breastfeeding, or planning to conceive within the studyperiod.

• Any experimental vaccine or gene therapy.

• History of cancer within the last 5 years.

• Current use of anticoagulant medications (e.g., coumadin, heparinoids, apixaban).

• Residence in a skilled nursing facility, convalescent home, or long term carefacility at screening; or requires continuous nursing care.